Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adalimumab (Humira)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    265 result(s) found for: Adalimumab (Humira). Displaying page 4 of 14.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-001066-17 Sponsor Protocol Number: CNTO1959PSO2001 Start Date*: 2012-04-10
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis (X...
    Medical condition: Moderate to Severe Plaque-type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005307-83 Sponsor Protocol Number: CL04041023 Start Date*: 2017-03-03
    Sponsor Name:R-Pharm
    Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheum...
    Medical condition: Moderately to Severely Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) CZ (Completed) DE (Completed) LT (Completed) HU (Completed) PL (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2014-000109-11 Sponsor Protocol Number: FKB327-002 Start Date*: 2015-01-22
    Sponsor Name:Fujifilm Kyowa Kirin Biologics Co., Ltd.
    Full Title: A Randomised, Blinded, Active-Controlled Study to Compare FKB327 Efficacy and Safety with the Comparator Humira® in Rheumatoid Arthritis Patients Inadequately Controlled on Methotrexate.
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-002078-23 Sponsor Protocol Number: M06-829 Start Date*: 2006-10-12
    Sponsor Name:Abbott GmbH & Co. KG (Abbott)
    Full Title: A Multi-Center, Open-Label Study of the Fully Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderate to Severe Crohn's Disease.
    Medical condition: Moderate to severe Crohn's Disease (Harvey Bradshaw Index score greater or equal to7).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) NO (Completed) FI (Completed) PT (Completed) SK (Completed) DE (Completed) IE (Completed) DK (Completed) FR (Completed) AT (Completed) GB (Completed) SE (Completed) GR (Completed) CZ (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-021449-28 Sponsor Protocol Number: PHRI10 – DM – AFORA Start Date*: 2010-10-04
    Sponsor Name:CHRU de TOURS
    Full Title: Valeur prédictive de la concentration sérique d’Adalimumab (Humira) sur la réponse clinique dans la polyarthrite rhumatoïde
    Medical condition: Polyarthrite rhumatoïde
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001816-56 Sponsor Protocol Number: HUM 05-064 Start Date*: 2006-05-11
    Sponsor Name:Rigshospitalet
    Full Title: Can PET scan be used to assess disease activity in patients with sarcoidosis during treatment with adalimumab (Humira)?
    Medical condition: sarcoidosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004614-26 Sponsor Protocol Number: ONS-3010-002 Start Date*: 2016-07-25
    Sponsor Name:Oncobiologics Limited
    Full Title: A Randomized, Double-Blind, Multicenter, Equivalence Study of ONS-3010 and Humira® for the Treatment of Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) PL (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000412-29 Sponsor Protocol Number: 17-23987 Start Date*: 2019-10-18
    Sponsor Name:F.I. Proctor Foundation, University of California San Francisco
    Full Title: Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial (ADJUST)
    Medical condition: juvenile-idiopathic arthritis paediatric uveitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10022557 Intermediate uveitis LLT
    20.0 100000004853 10033687 Panuveitis LLT
    20.1 100000004862 10036370 Posterior uveitis LLT
    20.1 100000004853 10066681 Acute uveitis LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-004468-23 Sponsor Protocol Number: version3.0 Start Date*: 2020-02-10
    Sponsor Name:St George's, University of London
    Full Title: Comparison of abatacept with tumor necrosis factor inhibitors in the treatment of rheumatoid arthritis pain: A phase IV trial
    Medical condition: Rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-000925-71 Sponsor Protocol Number: HUM 05-032 Start Date*: 2006-04-27
    Sponsor Name:University Hospital Ghent
    Full Title: TNF-blockade for the treatment of erosive osteoarthritis (OA) of interphalangeal finger joints. Randomized, double blind, placebo-controlled study to evaluate the efficacy of adalimumab 40 mg sc ev...
    Medical condition: Erosive interphalangeal osteoarthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000939-33 Sponsor Protocol Number: MLN0002-3026 Start Date*: 2015-11-11
    Sponsor Name:Takeda Development Centre Europe, Ltd.
    Full Title: A Randomized, Double-Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects With Ulcerative Colitis
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) NL (Completed) BG (Completed) GB (Completed) DE (Completed) HU (Completed) BE (Completed) ES (Completed) LV (Completed) EE (Completed) LT (Completed) PL (Completed) DK (Completed) PT (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006494-90 Sponsor Protocol Number: M06-807 Start Date*: 2008-11-24
    Sponsor Name:Abbvie Deutschland GmbH & Co. K.G.
    Full Title: A Multi-center, Open-label Study of the Human Anti−TNF Monoclonal Antibody Adalimumab to Evaluate the Efficacy and the Long-term Safety and Tolerability of Repeated Administration of Adalimumab in ...
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) GB (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-019441-26 Sponsor Protocol Number: P081210 Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Adalimumab dans l’Arthrite Juvénile Idiopathique pour le traitement de l’UVéITE (étude ADJUVITE)
    Medical condition: Uvéite dans l'arthrite Juvénile Idiopathique
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046851 Arthrite Idiopathique Juvénile PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000747-11 Sponsor Protocol Number: GP17-301 Start Date*: 2013-11-25
    Sponsor Name:Hexal AG
    Full Title: A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar adalimumab (GP2017) and Humira® in patients with moderate t...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-013072-52 Sponsor Protocol Number: M04-717 Start Date*: 2011-05-09
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicentre, Randomised, Double-Dummy, Double-Blind Study Evaluating Two Doses of Adalimumab versus Methotrexate (MTX) in Paediatric Subjects with Chronic Plaque Psoriasis (Ps)
    Medical condition: Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) CZ (Completed) HU (Completed) IT (Completed) Outside EU/EEA NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002411-29 Sponsor Protocol Number: M13-045 Start Date*: 2012-04-26
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: An Open-Label Multicenter Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting.
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10017947 Gastrointestinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) GB (Completed) DE (Completed) BE (Completed) DK (Completed) GR (Completed) PT (Completed) AT (Completed) IE (Completed) IT (Completed) FI (Completed) CZ (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-000082-38 Sponsor Protocol Number: HUM05-019 Start Date*: 2007-05-24
    Sponsor Name:Aarhus University Hospital, Denmark
    Full Title: The OPERA Study. Optimized treatment algorithm in early rheumatoid arthritis: Methotrexate and intra-articular glucocorticosteroid plus adalimumab or placebo in the treatment of early rheumatoid...
    Medical condition: In early RA methotrexate and intra-articular glucocorticoid in combination with adalimumab is better than methotrexate and intra-articular glucocorticoid in achieving control of the disease as asse...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-004139-31 Sponsor Protocol Number: M06-810 Start Date*: 2007-04-03
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Period, Double − Blind Study to Determine the Optimal Protocol for Treatment Initiation with Methotrexate and Adalimumab Combination Therapy in Patients with Early...
    Medical condition: Rheumatoid Arthritis.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) SK (Completed) ES (Completed) AT (Completed) FR (Completed) SE (Completed) CZ (Completed) DE (Completed) NL (Completed) HU (Completed) NO (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000542-18 Sponsor Protocol Number: 20200497 Start Date*: 2021-12-21
    Sponsor Name:Amgen Inc.
    Full Title: A Multicenter, Randomized, Double-blind Study Evaluating the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Multiple Switches Between Humira® (adalimumab [US]) and ABP 501 Compared With ...
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2015-004121-13 Sponsor Protocol Number: M13-687 Start Date*: 2015-11-17
    Sponsor Name:AbbVie GK
    Full Title: A Multicenter Open-label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Investigate Efficacy, Safety and Pharmacokinetics after Dose Escalation in Japanese Subjects with Crohn's Disease
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 20:33:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA